In addition, the GEM implant local delivery of gemcitabine inhibits tumor cell growth by promoting c-CBL-mediated EGFR degradation, thus inhibiting the proliferation, angiogenesis, and epithelial mesenchymal metastasis of pancreatic tumor (Hong et al., 2013; Jang et al., 2020). This evidence concerns the gene EGFR and neoplasm.